Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003.

The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30 by early 2026. Early data show the treatment is generally well-tolerated, there is evidence of stabilisation and improvement in cardiac function.

Solid has also started the process of screening for its Phase 3 study: Impact Duchenne.

Read the full press release here.

DRF is proud to have been an early funder of Solid Biosciences’ research, together with our friends at Duchenne UK and Joining Jack. Click here to learn more.